These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 23666249)

  • 1. Mineralocorticoid receptor throughout the vessel: a key to vascular dysfunction in obesity.
    Pojoga LH; Baudrand R; Adler GK
    Eur Heart J; 2013 Dec; 34(45):3475-7. PubMed ID: 23666249
    [No Abstract]   [Full Text] [Related]  

  • 2. Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity.
    Schäfer N; Lohmann C; Winnik S; van Tits LJ; Miranda MX; Vergopoulos A; Ruschitzka F; Nussberger J; Berger S; Lüscher TF; Verrey F; Matter CM
    Eur Heart J; 2013 Dec; 34(45):3515-24. PubMed ID: 23594590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mineralocorticoid receptors modulate vascular endothelial function in human obesity.
    Hwang MH; Yoo JK; Luttrell M; Kim HK; Meade TH; English M; Segal MS; Christou DD
    Clin Sci (Lond); 2013 Dec; 125(11):513-20. PubMed ID: 23786536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mineralocorticoid receptor antagonists and endothelial function.
    Maron BA; Leopold JA
    Curr Opin Investig Drugs; 2008 Sep; 9(9):963-9. PubMed ID: 18729003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute effect of mineralocorticoid receptor antagonism on vascular function in healthy older adults.
    Hwang MH; Yoo JK; Luttrell M; Kim HK; Meade TH; English M; Talcott S; Jaffe IZ; Christou DD
    Exp Gerontol; 2016 Jan; 73():86-94. PubMed ID: 26639352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of mineralocorticoid receptor/Rho/Rho-kinase pathway in obesity-related renal injury.
    Tokuyama H; Wakino S; Hara Y; Washida N; Fujimura K; Hosoya K; Yoshioka K; Hasegawa K; Minakuchi H; Homma K; Hayashi K; Itoh H
    Int J Obes (Lond); 2012 Aug; 36(8):1062-71. PubMed ID: 22184057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone.
    Hu X; Li S; McMahon EG; Lala DS; Rudolph AE
    Mini Rev Med Chem; 2005 Aug; 5(8):709-18. PubMed ID: 16101407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mineralocorticoid receptor antagonism induces browning of white adipose tissue through impairment of autophagy and prevents adipocyte dysfunction in high-fat-diet-fed mice.
    Armani A; Cinti F; Marzolla V; Morgan J; Cranston GA; Antelmi A; Carpinelli G; Canese R; Pagotto U; Quarta C; Malorni W; Matarrese P; Marconi M; Fabbri A; Rosano G; Cinti S; Young MJ; Caprio M
    FASEB J; 2014 Aug; 28(8):3745-57. PubMed ID: 24806198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eplerenone prevented obesity-induced inflammasome activation and glucose intolerance.
    Wada T; Ishikawa A; Watanabe E; Nakamura Y; Aruga Y; Hasegawa H; Onogi Y; Honda H; Nagai Y; Takatsu K; Ishii Y; Sasahara M; Koya D; Tsuneki H; Sasaoka T
    J Endocrinol; 2017 Dec; 235(3):179-191. PubMed ID: 28855315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contrasting effects of eplerenone and spironolactone on adrenal cell steroidogenesis.
    Ye P; Yamashita T; Pollock DM; Sasano H; Rainey WE
    Horm Metab Res; 2009 Jan; 41(1):35-9. PubMed ID: 18819053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eplerenone antagonizes atherosclerosis, but what is the agonist?
    Strawn WB
    Hypertension; 2005 Nov; 46(5):1093-4. PubMed ID: 16216993
    [No Abstract]   [Full Text] [Related]  

  • 12. [Roll of aldosterone in pathogenesis of kidney disorders].
    Kitamura K; Tomita K
    Nihon Naika Gakkai Zasshi; 2005 Jul; 94(7):1428-34. PubMed ID: 16097603
    [No Abstract]   [Full Text] [Related]  

  • 13. Recent studies with eplerenone, a novel selective aldosterone receptor antagonist.
    McMahon EG
    Curr Opin Pharmacol; 2001 Apr; 1(2):190-6. PubMed ID: 11714095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mineralocorticoid receptor antagonists, a class beyond spironolactone--Focus on the special pharmacologic properties of eplerenone.
    Seferovic PM; Pelliccia F; Zivkovic I; Ristic A; Lalic N; Seferovic J; Simeunovic D; Milinkovic I; Rosano G
    Int J Cardiol; 2015 Dec; 200():3-7. PubMed ID: 26404746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pleiotropic actions of aldosterone and the effects of eplerenone, a selective mineralocorticoid receptor antagonist.
    Takeda Y
    Hypertens Res; 2004 Nov; 27(11):781-9. PubMed ID: 15824460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist.
    Arai K; Homma T; Morikawa Y; Ubukata N; Tsuruoka H; Aoki K; Ishikawa H; Mizuno M; Sada T
    Eur J Pharmacol; 2015 Aug; 761():226-34. PubMed ID: 26073023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-Dose Mineralocorticoid Receptor Blockade Prevents Western Diet-Induced Arterial Stiffening in Female Mice.
    DeMarco VG; Habibi J; Jia G; Aroor AR; Ramirez-Perez FI; Martinez-Lemus LA; Bender SB; Garro M; Hayden MR; Sun Z; Meininger GA; Manrique C; Whaley-Connell A; Sowers JR
    Hypertension; 2015 Jul; 66(1):99-107. PubMed ID: 26015449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mineralocorticoid receptor blocker eplerenone improves endothelial function and inhibits Rho-associated kinase activity in patients with hypertension.
    Fujimura N; Noma K; Hata T; Soga J; Hidaka T; Idei N; Fujii Y; Mikami S; Maruhashi T; Iwamoto Y; Kihara Y; Chayama K; Kato H; Liao JK; Higashi Y;
    Clin Pharmacol Ther; 2012 Feb; 91(2):289-97. PubMed ID: 22205191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mineralocorticoid receptor function in bone metabolism and its role in glucocorticoid-induced osteopenia.
    Fumoto T; Ishii KA; Ito M; Berger S; Schütz G; Ikeda K
    Biochem Biophys Res Commun; 2014 May; 447(3):407-12. PubMed ID: 24713303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eplerenone for the treatment of cardiovascular disorders.
    Watanabe M; Krum H
    Expert Rev Cardiovasc Ther; 2012 Jul; 10(7):831-8. PubMed ID: 22908915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.